British Journal of Dermatology · 2019 · 101 citations · 12 references
MedicineDermatologyPediatricsPediatric DermatologyPediatric EpidemiologyPediatric TherapeuticsInfant Skin ConditionsInflammatory Skin DisordersSkin SafetyAdverse Drug EventsDermatologic Adverse EventsIvermectin TreatmentOral Ivermectin TherapyPediatric Dermatological TherapiesScabies In ChildrenScabies PruritusScabies Treatment
BACKGROUND: Scabies is a frequent condition seen in infants and children. Only topical treatments have been approved in infants, but some of them are poorly tolerated. Oral ivermectin is approved for the treatment of scabies in several countries, but its use in infants and children weighing < 15 kg is off label. OBJECTIVES: To assess the safety of ivermectin in infants and young children, and to collect data on ivermectin efficacy in these age groups. METHODS: This study was performed in the dermatology and paediatric dermatology departments of 28 French centres between July 2012 and November 2015. Physicians treating an infant or child weighing < 15 kg for scabies with oral ivermectin were asked to send back a completed standardized and anonymous questionnaire, and the data were analysed. RESULTS: (P < 0·001), and a delay between those two doses of < 10 days (P = 0·025). CONCLUSIONS: and when the delay between the two doses is < 10 days. Respond to this article.
12